Contraception
Volume 75, Issue 2 , Pages 131-135 , February 2007

Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated

  • Wesley Clark

      Affiliations

    • Gynuity Health Projects, New York, NY 10010, USA
    • ,
  • Tanya Panton

      Affiliations

    • Department of Family and Social Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
    • ,
  • Louisa Hann

      Affiliations

    • Department of Family and Social Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
    • ,
  • Marji Gold

      Affiliations

    • Department of Family and Social Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 718 920 2885; fax: +1 718 515 5416.

Received 7 September 2005 ,Revised 27 July 2006 ,Accepted 2 August 2006.

References 

  1. Blinder V, Elul B, Winikoff B. Mifepristone–misoprostol medical abortion: who will use it and why?. Am Obstet Gynecol. 1998;179:1376
  2. Boonstra H. Mifepristone in the United States: status and future. In: The Guttmacher report on public policy. 2002;p. 4–7
  3. Fielding SL, Schaff EA, Nam NY. Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. Contraception. 2002;66:27–31
  4. Newhall E, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol. 2000;183(Suppl 2):S44–S53
  5. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays and ultrasonography in medical abortion practice. Am Obstet Gynecol. 2000;183(Suppl 2):S34–S43
  6. Taipale P, Hiilesmaa V. Predicting delivery date by ultrasound and last menstrual period in early gestation. Obstet Gynecol. 2001;97:189–194
  7. McGalliard C, Gaudoin M. Routine ultrasound for pregnancy termination requests increases women's choice and reduces inappropriate treatments. Br J Obstet Gynecol. 2004;111:79–82
  8. Lagrew DC, Wilson EA, Jawad MJ. Determination of gestational age by serum concentrations of human chorionic gonadotropin. Obstet Gynecol. 1983;62:37–40
  9. Creinin MD. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Am Obstet Gynecol. 1996;174:776–778
  10. Schaff E, Walker K, Fielding S, Fuller L. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. Contraception. 2001;64:271–273
  11. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion: ultrasound versus hCG testing. Eur Obstet Gynecol Reprod Biol. 2003;109:190–195

☆ There was no funding for this study.

PII: S0010-7824(06)00314-3

doi: 10.1016/j.contraception.2006.08.001

Contraception
Volume 75, Issue 2 , Pages 131-135 , February 2007

Article Tools